Reaction

Post-Acute Covid-19 Syndrome reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,220 reports · 35 co-occurring drugs

As of the last recalculation, Post-Acute Covid-19 Syndrome appears in 1,220 FAERS reports alongside 35 co-occurring drug terms. The strongest observed disproportionality signal is HUMAN IMMUNOGLOBULIN G (PRR 60.4).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Human Immunoglobulin G	69	60.4	60.6
Obinutuzumab	53	57.4	57.6
Bendamustine Hydrochloride	28	40.8	40.9
Calcium, Magnesium, Potassium, And Sodium Oxybates	20	40.3	40.4
Remdesivir	28	36.7	36.7
Nirmatrelvir And Ritonavir	84	28.4	28.4
Diphenhydramine Hydrochloride Capsule, Liquid Filled	34	27.9	27.9
Bendamustine Hcl	18	20.1	20.1
Baricitinib	11	19.6	19.7
Tiotropium Bromide Inhalation Spray	12	18.4	18.5
Adrenalinum	41	17.4	17.4
Polatuzumab Vedotin	9	15.8	15.9
Rituximab	165	15.2	15.3
Ifosfamide	16	12.9	12.9
Azelastine	12	11.5	11.5
Benralizumab	13	11.2	11.2
Doxyclycline Hyclate	11	11.1	11.1
Epinephrine	41	11.0	11.0
Carboxymethylcellulose Sodium	6	10.9	10.9
Ocrelizumab	38	10.8	10.8
Axicabtagene Ciloleucel	6	10.4	10.4
Elexacaftor, Tezacaftor, And Ivacaftor	7	9.6	9.6
Avapritinib	6	8.5	8.5
Nintedanib	14	7.7	7.7
Fexofenadine Hydrochloride	9	7.1	7.1
Doxorubicin	35	6.9	6.9
Asfotase Alfa	4	6.8	6.8
Rucaparib	3	5.8	5.8
Eptinezumab-Jjmr	3	5.6	5.6
Fluticasone Furoate, Umeclidinium Bromide And Vilanterol Trifenatate	13	5.4	5.4
Rimegepant Sulfate	4	5.4	5.4
Suvorexant	4	5.3	5.3
Diroximel Fumarate	3	4.3	4.3
Voxelotor	4	3.0	3.0
Galcanezumab-Gnlm	5	2.7	2.7

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.